Pages
Products
Human ETV6-SYK Stable Cell Line - BaF3

Human ETV6-SYK Stable Cell Line - BaF3

Cat.No. :  CSC-RO0368 Host Cell:  Ba/F3

Size:  >1x10^6 frozen cells/vial, 1 mL Stability:  Stable in culture over a minimum of 10 passages

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Cat. No. CSC-RO0368
Description This cell line is engineered to stably overexpress exogenous human ETV6-SYK fusion protein.
Target Gene ETV6-SYK
Gene Species Homo sapiens (Human)
Host Cell Ba/F3
Host Cell Species Mus musculus (Mouse)
Stability Stable in culture over a minimum of 10 passages
Application Drug screening and biological assays
Growth Conditions 37 °C, 5% CO2
Quality Control Negative for bacteria, yeast, fungi and mycoplasma.
Shipping Dry ice
Storage Liquid nitrogen
Size >1x10^6 frozen cells/vial, 1 mL
Biosafety Level 2
Thawing & Subculturing Instructions 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap.

2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely.

3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min.

4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker).

5. Incubate the culture at 37°C with 5% CO2.

6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL.
Growth Properties Suspension, round
Freeze Medium Frozen with 70% medium, 20% FBS, 10% DMSO
Freezing Instructions Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker).

1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use.

2. Keep the freezing medium on ice and label cryovials.

3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.

4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium.

5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium.

6. Aliquot 1 ml of the cell suspension into each cryovial.

7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.

8. Transfer vials to liquid nitrogen for long-term storage.
Mycoplasma Negative
Format One frozen vial containing millions of cells
Storage Liquid nitrogen
Safety Considerations

The following safety precautions should be observed.

1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum.

2. No eating, drinking or smoking while handling the stable line.

3. Wash hands after handling the stable line and before leaving the lab.

4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells.

5. All waste should be considered hazardous.

6. Dispose of all liquid waste after each experiment and treat with bleach.

Ship Dry ice
Quick Inquiry

Background

Applications

Publications

Q & A

Customer Reviews

The ETV6-SYK fusion gene is a unique gene rearrangement that occurs in certain types of cancer, most commonly in patients with childhood acute lymphoblastic leukaemia (ALL). The fusion gene consists of the ETV6 gene, which is involved in the regulation of gene expression, and the SYK gene, which encodes a non-receptor tyrosine kinase. The ETV6-SYK fusion gene produces a hybrid protein with altered kinase activity that disrupts normal cell signalling pathways and promotes the growth, survival and proliferation of cancer cells. The fusion protein was found to be constitutively active, i.e., always "on", which leads to uncontrolled growth of cancer cells. This fusion gene has been associated with a subtype of paediatric ALL known as "Philadelphia-like" ALL, which also includes the BCR-ABL1 fusion gene. The ETV6-SYK fusion gene is usually found in patients with specific genetic backgrounds and clinical features, such as a high frequency of myeloid hyperdiploidy and a low frequency of TCF3 mutations. The presence of the ETV6-SYK fusion gene in paediatric ALL patients has important implications for their treatment and prognosis. Targeted therapies that specifically inhibit the activity of the fusion protein are being investigated as a potential treatment for patients with this specific genetic alteration.
The Human ETV6-SYK Stable BaF3 Cell Line is an important tool for researchers to study the function and signalling pathways of the ETV6-SYK fusion gene.The ETV6-SYK fusion gene is the result of a fusion of the ETV6 gene and the SYK gene, which produces a fusion protein with abnormal kinase activity. This stable cell line can be used to study the effects of the ETV6-SYK fusion gene on cell growth, survival and proliferation. It can also be used to study the downstream signalling pathways of the mutated SYK protein, which is important for understanding the pathogenesis of leukaemia and developing targeted therapies. By using this cell line, researchers can test the efficacy of new drugs and inhibitors that specifically target mutant SYK proteins, providing an important tool for the development of personalised medical treatments for leukaemia patients with this specific fusion gene. In conclusion, the human ETV6-SYK stable cell line, BaF3, is an important model for studying the function and signalling pathways of the ETV6-SYK fusion gene in leukaemia, and it plays an important role in the research and development of new targeted therapies for this aggressive leukaemia.
Customer Q&As
What is the ETV6-SYK gene and its significance in hematopoietic malignancies?

A: The ETV6-SYK gene represents a fusion oncogene that arises from the fusion of the ETV6 (ETS variant 6) and SYK (spleen tyrosine kinase) genes. This fusion is commonly detected in certain hematopoietic malignancies, particularly acute lymphoblastic leukemia (ALL) and sometimes in myelodysplastic syndromes. It is considered a driver of leukemogenesis, contributing to uncontrolled cell growth and survival.

How does the ETV6-SYK fusion gene contribute to leukemogenesis?

A: The ETV6-SYK fusion gene contributes to leukemogenesis by activating aberrant signaling pathways. The fusion event results in the constitutive activation of the SYK kinase domain, leading to uncontrolled cell proliferation, inhibition of apoptosis, and leukemic transformation. This fusion is known to dysregulate normal hematopoiesis and lead to the development of leukemia.

Are there any therapeutic implications of targeting the ETV6-SYK fusion gene?

A: Targeting the ETV6-SYK fusion gene has therapeutic implications for the treatment of hematopoietic malignancies. Specifically, targeted therapies such as tyrosine kinase inhibitors (TKIs) and other drugs that can inhibit the signaling pathways activated by the fusion protein are being explored. These treatments aim to slow or stop the progression of leukemia cells with ETV6-SYK rearrangements.

How is the ETV6-SYK fusion gene detected and diagnosed?

A: The ETV6-SYK fusion gene is detected through a variety of molecular diagnostic methods, including reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). These techniques can identify the specific fusion event, allowing for accurate diagnosis and prognosis of patients with hematopoietic malignancies associated with this fusion gene.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Delivery System

The Human ETV6-SYK Stable Cell Line - BaF3 is securely delivered using an efficient and reliable system, ensuring the integrity of the cells during transit and minimizing the risk of damage or contamination.

United Kingdom

01/15/2020

Shipping and Storage Conditions

The cell line is shipped and stored under optimized conditions, including proper temperature and handling, to maintain cell viability and functionality, allowing researchers to receive the cells in optimal condition for their experiments.

French

12/10/2022

Application Range

The Human ETV6-SYK Stable Cell Line - BaF3 has a wide range of applications in cancer research, particularly in studying the pathogenesis and developing potential therapies for ETV6-SYK-related hematological malignancies.

United Kingdom

01/11/2022

Legal and Intellectual Property

The Human ETV6-SYK Stable Cell Line - BaF3 complies with all legal and intellectual property requirements, ensuring that researchers can use the cell line confidently, knowing that they are adhering to ethical and legal standards in their work.

Canada

05/01/2020

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction